Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
Pre-publication versions of this article are available by contacting email@example.com.
|16 Feb 2012||Submitted||Original manuscript|
|Resubmission - Version 2|
|Submitted||Manuscript version 2|
|8 Jun 2012||Reviewed||Reviewer Report - Nikoletta Lendvai|
|16 Jun 2012||Reviewed||Reviewer Report - Craig Hofmeister|
|6 Jul 2012||Author responded||Author comments - Roman Hajek|
|Resubmission - Version 3|
|6 Jul 2012||Submitted||Manuscript version 3|
|24 Jul 2012||Author responded||Author comments - Roman Hajek|
|Resubmission - Version 4|
|24 Jul 2012||Submitted||Manuscript version 4|
|31 Jul 2012||Editorially accepted|
|19 Sep 2012||Article published||10.1186/1471-2407-12-415|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.